Abstract
Intraperitoneal administration of (−)-sulpiride (12 to 50 mg/kg) produced a dose-related decrease in cGMP content in cerebellar cortex, while the (+)-enantiomer was completely inactive. The same results were also obtained after intrastriatal injection of (−)- and (+)-sulpiride (10 μg), but not after intracerebellar injection. These findings support the contention that (−)-sulpiride modifies cerebellar cGMP levels through an action on striatal dopamine receptors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
